Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 109
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Closed
18 and over
Pharmaceutical / Industry
ML18530
NCT00127933
Last Modified:
1/15/2008
 
First Published:
8/1/2001
2.
Phase II/III Randomized Study of Anastrozole With or Without Trastuzumab (Herceptin) in Postmenopausal Women With Hormone-Receptor Positive HER2-Overexpressing Metastatic Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
ROCHE-BO16216
CWRU-030118, GENENTECH-H2223g, ROCHE-1100, ROCHE-B016216F, NCT00022672
Last Modified:
9/1/1995
3.
Phase III Randomized Study of Chemotherapy with vs without Monoclonal Antibody HER2 in Women with Metastatic Breast Cancer Overexpressing HER2/neu and Previously Untreated with Cytotoxic Chemotherapy (Summary Last Modified 09/95)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 to 75
Pharmaceutical / Industry
GENENTECH-HO648G
NCI-V95-0714
Last Modified:
7/1/1998
4.
Phase III Randomized, Single-Blind Study of Monoclonal Antibody HER2 in Chemotherapy-Naive Metastatic Breast Cancer That Overexpresses HER2/neu (Summary Last Modified 07/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
Pharmaceutical / Industry
UCLA-HSPC-9510492
NCI-V96-0947
Last Modified:
12/22/2008
 
First Published:
9/1/1998
5.
Phase III Randomized Study of Paclitaxel Via One-Hour Infusion Every Week Versus Three-Hour Infusion Every 3 Weeks With or Without Trastuzumab (Herceptin®) in Women With Inoperable, Recurrent, or Metastatic Breast Cancer With or Without Overexpression of HER2/neu
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
NCI
CLB-9840
NCT00003440, CALGB-9840
Last Modified:
9/23/2008
 
First Published:
10/1/1999
6.
Phase III Randomized Study of Doxorubicin and Cyclophosphamide Followed By Paclitaxel With or Without Trastuzumab (Herceptin®) in Women With Node-Positive Breast Cancer That Overexpresses HER2
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
Not specified
NCI
NSABP-B-31
NCT00004067
Last Modified:
1/6/2009
 
First Published:
7/1/2000
7.
Phase III Randomized Study of Doxorubicin Plus Cyclophosphamide Followed By Paclitaxel With or Without Trastuzumab (Herceptin®) in Women With HER-2-Overexpressing Node-Positive or High-Risk Node-Negative Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
NCI
NCCTG-N9831
CALGB-49909, ECOG-N9831, SWOG-N9831, GUMC-00224, N9831, NCT00005970, CAN-NCIC-MA28, MA28
Last Modified:
8/2/2007
 
First Published:
5/1/2001
8.
Phase III Randomized Study of Doxorubicin and Cyclophosphamide With or Without Dexrazoxane, Followed By Paclitaxel With or Without Trastuzumab (Herceptin), Followed By Surgery and Radiotherapy With or Without Trastuzumab in Women With HER-2+ Stage IIIA or IIIB or Regional Stage IV Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care, Treatment
Completed
18 and over
NCI
CLB-49808
NCT00016276, CALGB-49808
Last Modified:
9/23/2008
 
First Published:
7/1/2001
9.
Phase III Randomized Study of Adjuvant Doxorubicin, Cyclophosphamide, and Docetaxel With or Without Trastuzumab (Herceptin) Versus Trastuzumab, Docetaxel, and Either Carboplatin or Cisplatin in Women Who Have Undergone Surgery For HER2-neu-Expressing Node-Positive or High-Risk Node-Negative Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 to 70
NCI, Pharmaceutical / Industry
AVENTIS-TAX-GMA-302
UCLA-0102006, BCIRG-006, UAB-0106, UAB-F010326012, NCI-G01-1978, NCT00021255
Last Modified:
9/23/2008
 
First Published:
9/1/2002
10.
Phase III Randomized Study of Trastuzumab (Herceptin®) Versus No Herceptin in Women With HER-2 Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
Other, Pharmaceutical / Industry
BIG-01-01
EU-20216, ROCHE-B016348E, ROCHE-B016348C, EORTC-10011, CAN-NCIC-MA24, IBCSG-28-02, NCT00045032, MA24
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute